pDNA2.0 6H-TEV-KRAS G13D
(Plasmid
#111851)
-
PurposeExpresses activated human KRAS G13D (amino acids 1 - 169) in E. coli with amino terminal 6xHIS tag that can be removed with TEV protease.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 111851 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepDNA2.0
-
Backbone manufacturerATUM
- Backbone size w/o insert (bp) 3939
- Total vector size (bp) 4500
-
Modifications to backboneNone
-
Vector typeBacterial Expression
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameKRAS G13D
-
Alt nameKirsten ras oncogene G13D
-
SpeciesH. sapiens (human)
-
Insert Size (bp)507
-
MutationChanged Glycine 13 to Aspartic Acid
-
Entrez GeneKRAS (a.k.a. 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2)
- Promoter T5
-
Tags
/ Fusion Proteins
- 6xHis-tag (N terminal on backbone)
- TEV protease cleavage sequence (N terminal on backbone)
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer GGAATTGTGAGCGCTCACAA
- 3′ sequencing primer GAACTGCCAGGCATCAAATAAAA (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pDNA2.0 6H-TEV-KRAS G13D was a gift from Kenneth Westover (Addgene plasmid # 111851 ; http://n2t.net/addgene:111851 ; RRID:Addgene_111851) -
For your References section:
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Mol Cancer Res. 2015 Sep;13(9):1325-35. doi: 10.1158/1541-7786.MCR-15-0203. Epub 2015 Jun 2. 10.1158/1541-7786.MCR-15-0203 PubMed 26037647